Iron-Based Core-Shell Nanowires for Combinatorial Drug Delivery and Photothermal and Magnetic Therapy.
Cell Line, Tumor
Cell Survival
/ drug effects
Doxorubicin
/ chemistry
Drug Carriers
/ chemistry
Drug Delivery Systems
/ instrumentation
Ferric Compounds
/ chemistry
Humans
Hyperthermia, Induced
/ instrumentation
Iron
/ chemistry
Light
Nanowires
/ chemistry
Neoplasms
/ drug therapy
Phototherapy
/ instrumentation
drug delivery
iron−iron oxide core−shell
magnetic cancer therapy
nanowires
photothermal therapy
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
27 Nov 2019
27 Nov 2019
Historique:
pubmed:
5
11
2019
medline:
9
4
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
Combining different therapies into a single nanomaterial platform is a promising approach for achieving more efficient, less invasive, and personalized treatments. Here, we report on the development of such a platform by utilizing nanowires with an iron core and iron oxide shell as drug carriers and exploiting their optical and magnetic properties. The iron core has a large magnetization, which provides the foundation for low-power magnetic manipulation and magnetomechanical treatment. The iron oxide shell enables functionalization with doxorubicin through a pH-sensitive linker, providing selective intracellular drug delivery. Combined, the core-shell nanostructure features an enhanced light-matter interaction in the near-infrared region, resulting in a high photothermal conversion efficiency of >80% for effective photothermal treatment. Applied to cancer cells, the collective effect of the three modalities results in an extremely efficient treatment with nearly complete cell death (∼90%). In combination with the possibility of guidance and detection, this platform provides powerful tools for the development of advanced treatments.
Identifiants
pubmed: 31682404
doi: 10.1021/acsami.9b17512
doi:
Substances chimiques
Drug Carriers
0
Ferric Compounds
0
ferric oxide
1K09F3G675
Doxorubicin
80168379AG
Iron
E1UOL152H7
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM